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ABSTRACT 
In our previous study, we reported the expression of a recombinant single chain fragment 
variable (scFv) antibody that recognized blood type A antigen (antiA-scFv) in E. coli. When it 
was expressed as it is alone, antiA-scFv was produced as inclusion body. In contrast, SM/antiA-
scFv was synthesized in soluble form when it was fused to small ubiquitin modifier (SUMO). 
Here, we present the extraction and purification of antiA-scFv in the inclusion body as well as in 
the soluble form and evaluate the antiA-scFv antibody activity. The results show that only fusion 
expression of soluble SM/antiA-scFv has biological activity of the antibody. SM/antiA-scFv was 
separated by fractional precipitation with 20% ammonium sulfate, and then washed with buffers 
to collect the pure antiA-scFv with SUMOprotease treatment. The purity of recombinant 
antibody was 89% and the yield of 64.9 mg/L of bacterial culture. The antibody has a polymer 
structure and could bind to purified antigen as well as agglutinate with red blood cell, but the 
specificity of the antibody was not good enough for the antigen and red blood cell of blood type 
A. This is the first report in Vietnam showing the extraction and purification of the recombinant 
single chain antibody recognizing antigen of ABO system using E. coli expression system. It can 
be considered as a reference for further studies to improve the specificity of recombinant 
antibody antiA-scFv to identify ABO-type blood antigens. 
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INTRODUCTION 
The production of antibodies by 
hybridoma technology has been successfully 
applied in many areas of research, medical 
diagnostic and therapeutic applications such 
as in treatment of autoimmune diseases, 
infectious diseases and oncological diseases 
(Frenzel et al., 2013). However, in many 
cases, pure antigen is not available to induce 
immunity, especially with surface antigens or  
membrane protein antigens. These antigens 
are easy to lose their structures during 
purification process. Besides, hybridoma 
technology also has several limitations in cell-
cell fusion mechanisms so that the fused 
hybrid cells (hybridomas) used in antibody 
production are unsustainable. Moreover, the 
production of monoclonal antibodies using 
hybridoma technology is very labourious and 
costly due to high-cost culture media for 
animal cells, strictly controlled cell culture 
conditions as well as storage conditions. 
With the development of recombinant 
protein technology, single chain fragment 
variable (scFv) recombinant antibody, one of 
the most popular types of recombinant 
antibodies, is easily expressed in a functional 
form in E. coli (Ahmad et al., 2012; Spadiut et 
al., 2014). E. coli expression system is the 
most commonly used economical expression 
system because of its simple structure, well-
known genetic background, high yield of 
target protein and its short generation time. 
Furthermore, scFv can also be genetically 
modified to enhance desirable properties such 
as affinity and specificity (Song et al., 2014). 
 However, the insoluble inclusion body 
formation of scFvs expressed in E. coli 
which often leads to low binding activity, 
unstable structure and toxic effect to host 
cells, is a significant obstacle. Another 
concern is the inability of bacteria to carry 
out eukaryotic post-translational 
modifications (PTMs) which is required by 
protein to fold and is therefore not suitable 
when glycosylation of antibody fragments or 
the fusion protein is required.  
A variety of approaches to increase the 
expression and the proper folding as well as 
solubility of desired protein have been 
developed: (1) changing the vector, (2) 
changing the host strain, (3) adding of some 
chemicals during the induction, or (4) co-
expression with other genes, (5) changing the 
gene sequences without changing the 
functional domain of protein.  
Recombinant protein expressed 
intracellularly in the reduced environment of 
cytoplasm frequently forms in a insoluble 
inclusion bodies lacking biological activity 
(Wörn et al., 2000). Strategies to solubilize 
inclusion bodies under the presence of 
denaturing agents, followed by the refolding 
of the protein to regain function are not 
always successful. However, if a secretion 
vector is used, they can form in the 
periplasmic space which is advantageous in 
terms of protein folding and solubility. The 
antigen-binding fragment of an antibody was 
expressed as a fully functional and stable 
protein in E. coli in the oxidized periplasm 
that contributed to the correct formation of the 
intramolecular disulfide bonds and the hetero-
association of the variable domains (Skerra & 
Plückthun, 1988). On the other hand, 
cysteine-free mutant antibody scFv lacking 
the conserved disulfide bonds could be 
expressed in a stable and functional form in 
the E. coli cytoplasm (Proba et al., 1998). 
Moreover, mutation of genes coding 
glutathione and thioredoxin reductase in host 
strains and co-expression of chaperones such 
as GroEL/ES, DnaK/J, DsbC, Skp, GroES/L, 
peptidyl prolyl-cis, transisomerase FkPa were 
applied to improve functional production of 
recombinant proteins (Bothmann & 
Plückthun, 2000; Friedrich et al., 2010). 
MATERIALS AND METHODS 
E. coli strains expressing recombinant 
protein antiA-scFv and protein SM/antiA-
scFv generated from our previous study was 
used in this research (Dang et al., 2017). 
The following reagents, chemicals, 
antibodies were also used in this study: 
ammonium persulfate (APS), N,N,N',N'-
Tetramethyl-ethylenediamine (TEMED), 
glycerol, glycine, ethanol, methanol, SDS, 
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Tris, acrylamide, bis-acrylamide, coomassie, 
amonium sulfate (Merck, Germany); 
skimmilk (Difco, USA); ampiciline, 3,3′,5,5′-
tetramethylbenzidine (TMB), ethylene 
glycol bis(succinimidyl succinate (EGS), 
ficin (Sigma, USA); Blood group A-BSA, B-
BSA, BSA (Dextra, UK); red blood cells 
(National Institute of Hematology and Blood 
Transfusion, Vietnam); mouse monoclonal 
antibody against c-myc 1 mg/ml, peoxidase-
labelled anti-mouse IgG (Sigma, USA). 
Extraction of recombinant antiA-scFv from 
E. coli 
After fermentation, the recombinant E. 
coli cells were harvested by centrifugation at 
5,000 rpm for 10 min and resuspended in 20 
mM Tris HCl, pH=8 to reach an optical 
density (OD600nm) of 10. The cells were lysed 
by sonication on ice for 10 min at the 
frequency of 20 kHz. After sonication, the 
pellet was separated from the supernatant by 
centrifugation at 8,000 rpm in 10 min and 
subsequently resuspended in a equivalent 
volume in 20 mM Tris HCl, pH=8. Proteins in 
soluble and insoluble fractions were both 
examined by SDS-PAGE 12.6% (Laemmli 
1970). 
Denaturing purification of recombinant 
antiA-scFv 
The inclusion bodies of recombinant 
antiA-scFv in 50 ml cell lysate were pelleted 
by centrifugation. The pelleted protein was 
solubilized in 15 ml of denaturing buffer, 6 
M Guanidine-HCl. Residual insoluble matter 
was removed by centrifugation at 8,000 rpm 
for 10 min. The supernatant was collected 
and then loaded to the affinity 
chromatography column along with binding 
buffer (20 mM sodium phosphate; 0.5 M 
NaCl, 5 mM imidazol; 6 M GuHCl, pH=8). 
The non-binding proteins were washed with 
10 column volume (CV) of binding buffer. 
The weakly bound proteins were washed 
with 10 CV of washing buffer (20 mM 
sodium phosphate; 0.5 M NaCl, 50 mM 
imidazol; 6 M GuHCl, pH=8). The bound 
proteins were eluted from the column in 2-ml 
fractions with elution buffer (20 mM sodium 
phosphate; 0.5 M NaCl; 400 mM imidazol; 6 
M GuHCl; pH=8). The protein concentration 
in load, flow-through, wash and eluted 
fractions were determined by nanodrop. The 
refolding of eluted protein was performed 
using different buffer systems and its activity 
was checked.  
Purification of soluble recombinant antiA-
scFv 
The antiA-scFv fused with SUMO 
(SM/antiAscFv) was expressed successfully in 
a soluble form (Dang et al., 2018) and the 
fusion protein was subsequently purified 
using Ni Sepharose affinity matrix to purify 
histidine-tagged protein. However, SM/antiA-
scFv was stuck on the resin and was not 
eluted from the chromatography column even 
with 1 M imidazole.  Thus, we had to change 
the purification strategy. 
To purify SM/antiA-scFv by ammonium 
sulfate precipitation, 15% w/v (NH4)2SO4 was 
added to the solution containing total soluble 
protein at 4
o
C. After incubation at 4
o
C for 30 
min, the solution was centrifuged and both 
pellet and supernatant were collected. 
(NH4)2SO4 was continuously added to the 
supernatant at the final concentration of 20% 
w/v to further precipitate protein containing 
SM/antiA-scFv. The precipitate was collected 
by centrifugation and washed with 20 mM 
Tris-HCl pH 8. 
Cleavage of SUMO from SM/antiA-scFv 
by SUMO protease: The insoluble SM/antiA-
scFv obtained after precipitation was 
cleaved with 0.025 U of SUMO protease at 
30
o
C for 3 hr (One enzyme unit will cut 100 
µg substrate at the enzyme activity of 3,333 
U/mg) in PBS pH 7.4 containing 2 mM DTT. 
After cleavage, the mixture was centrifuged at 
8,000 rpm in 10 min. The supernatant was 
discarded and the pellet containing insoluble 
antiA-scFv was obtained. 
To solubilize antiA-scFv pellet, insoluble 
antiA-scFv was washed with PBS pH 7.4 with 
0.02% Tween-20 and 1% Triton X-100 and 
then solubilized in buffer containing 5% 
glycerol, 71.5 mM mercaptoethanol and 
0.05% SDS. The solution was centrifuged at 
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8,000 rpm for 10 min to remove any 
remaining debris and collect the supernatant 
containing solubilized antiA-scFv. Then, 
antibody solution was loaded into a dialysis 
bag with a membrane molecular weight cut-
off of 3 kDa and dialysed against PBS pH 7.4 
with 5% glycerol. The concentration of 
soluble antiA-scFv was determined using a 
Nanodrop Spectro-photometer at  280 nm. 
The purity of the product was evaluated 
by SDS-PAGE using Quantity One software 
(Biorad, UK). The bioactivity of recombinant 
antiA-scFv was assessed by ELISA using pure 
blood antigens and by the hemagglutination 
test using red blood cells.  
Western blot analysis 
Following SDS-PAGE, protein was 
transferred from gel onto PVDF blotting 
membrane at 15–20 V for  15 min using the 
Trans-blot Semi-dry system (Biorad, UK). 
Protein scFv was detected by Western blot 
using monoclonal antibody against C-myc 
(Dang et al., 2017). Briefly,  membrane was 
incubated with 1,000-fold diluted primary 
antibody (antibody against C-myc) in 10 ml of 
5% skimmed milk for 1 hr and then with 
5,000-fold diluted secondary antibody (anti 
mouse IgG-peroxidase) in 10 ml 5% skimmed 
milk for another 1 hr. The detection was 
carried out by adding TMB substrate.  
Enzyme-linked immunosorbent assay 
(ELISA) 
100 µl each of antigen A/BSA, antigen 
B/BSA, and BSA (at concentration of 5 
µg/ml in coating buffer) was added to each 
well of a flat bottom 96-well ELISA 
microtiter plate and incubated the plate 
overnight at 4
o
C. After incubation, the 
solution was removed and the plated was 
washed with 200 µl wash buffer per well. 
Then 200 µl of blocking buffer was added to 
each well and the plate was incubated at 
room temperature (RT) for 30 min. The wells 
were washed 3 times with 200 µl wash buffer 
and 100 µl antiA-scFv (25 µg) was added to 
each well and incubated at RT for 60 min. 
The wells were washed 3 times with 200 µl 
wash buffer, and the conjugated secondary 
antibody (anti c-Myc antibody diluted 1000 
times from stock 1 mg/ml) was added to each 
well and the plate was incubated at RT for 60 
min. The solution was removed and the plate 
was washed 3 times. The 5000-fold diluted 
conjugated third antibody (anti-mouse IgG-
peoxidase) was added to each well and the 
plate was incubated at RT for 60 min. The 
solution was removed and the plate was 
washed 3 times. The substrate solution was 
prepared by mixing acetate buffer, TMB and 
H2O2 and added to each well and incubated 
at RT within 5–30 min for colouring. The 
reaction was stopped by adding 100 µl of 
2 M H2SO4 per well. The absorbance was 
measured at 450 nm. 
Hemagglutination assay 
A round-bottomed 96-well plate is 
preferred for this assay. To each well, 50 µl 
PBS pH 7.4 was added, then 50 µl of 
recombinant antiA-scFv solution at 0.5 
mg/ml concentration was pipetted into the 
first column and serial two fold dilution of 
the recombinant protein was prepared. 
Then, 5 µl of 5% red blood cells was added 
to each well (type A: first row, type B: 
second row, type O: third row) and the plate 
was mixed gently. Negative control was 
PBS pH 7.4 without adding any type of 
blood cell. The plate was left at RT for 1 hr 
then the end=point of hemagglutination was 
visually determined. The antibody antiA-
scFv being treated with 1 mM EGS at 25
o
C 
for 30 min was also tested for its 
hemagglutination ability. Moreover, the 
hemagglutination test using ficin-treated red 
blood cells was also performed. For this, red 
blood cells type A (5%) was centrifuged at 
4,000 rpm for 5 min and the supernatant 
was discarded.  The red cells were washed 3 
times with PBS pH 7,4 and then incubated 
with 0.1% ficin at 37
o
C for 15-30 min. The 
mixture was centrifuged at 4,000 rpm for 5 
min and the supernatant was discarded. The 
red cells were washed 3 times with PBS pH 
7.4 and resuspended in the equivalent 
volume of PBS pH 7.4 to reach the prior 
concentration of 5%.  
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RESULTS 
Purification and refolding of antiA-scFv 
In the previous publication, we reported 
the result of production of antiA-scFv in E. 
coli using vector pET22b(+) as an expression 
vector (Dang et al., 2017). As the protein was 
expressed in the inclusion body form, the 
strategy for handling this protein including 
isolation of inclusion bodies, solubilization 
and refolding was necessary.  
6M GuHCl was used to denature the 
insoluble antiA-scFv. The solubilised 
protein was then purified in denaturation 
condition using affinity chromatography (as 
protein was designed histidine-tagged). As 
shown in the chromatogram, the elution step 
at 400 mM imidazole produced one high 
peak. In the flow-through and wash steps, 
however, several minor peaks were 
observed which could be related to non-
binding and non-specific binding proteins 
(Fig. 1a). Protein concentrations in each 
phase of chromatography as well as in the 
starting material (before loading to the 
column) were quantified by Nanodrop and 
the results were shown in Table 1. The 
elution fractions (E1-E7) contained the 
greatest amount of protein. Total amount of 
protein obtained in the elution step was 
11.97 mg, equivalent to approximately 60% 
of the protein loaded on the column. The 
third elution fraction had the highest protein 
concentration of 2.4 mg/ml. 
 
Table 1. Amount of protein in chromatography fractions 
Phases of affinity chromatography 
Protein concentration 
(mg/ml) 
Volume 
(ml) 
Total protein 
(mg) 
Input sample before loading to column (TS) 1.34 15 20.10 
Flow-through fraction (F) 0.22 16    3.52 
Wash fraction 0.08 50  4.0 
Elution fraction 
E1 0.21 2 
 
 
 
11.97 
E2 1.29 2 
E3 2.40 2 
E4 1.24 2 
E5  0.51 2 
E6 0.22 2 
E7 0.11 2 
 
Based on SDS-PAGE analysis (Fig. 1b), 
the non-specifically bound proteins were 
removed during flow-through and wash 
fractions. Meanwhile, the target protein, 
antiA-svFv, bound efficiently to the resin and 
was collected only at the elution step with 400 
nM imidazol. AntiA-scFv was the 
predominant protein fraction in the elution 
fractions 2, 3 and 4 (E2-4), consistent with the 
Nanodrop results. Thus, we concluded that the 
purification of antiA-scFv under denaturing 
condition was successful.  
In order to regain biological fuction, after  
denaturing and purification, the refolding of 
antiA-scFv was performed by dialysing 
against buffer consisting of 50 mM Tris pH8, 
8 mM KCl, 400 mM L-arginine, 2 mM GSH, 
0.4 mM GSSG, 1mM EDTA to remove 
denaturing agents and allow the formation of 
the correct intramolecular associations. 
Refolded protein was incubated with EGS, an 
agent allowing proteins to be trimeric by 
chemical cross-linking. However, the refolded 
protein was still not active in 
hemagglutination test (data not shown), which 
means the recombinant antiA-scFv was 
produced without bioactivity.  
Therefore, modifications in expression 
system aiming at enhancement of the soluble 
expression were considered. One of them 
was the use of SUMO fusion protein 
expression system. 
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Figure 1. Affinity purification of recombinant antiA-scFv. (a). Chromatogram. Flow: the 
unbound proteins were removed when loading sample to the column; Binding: the unbound 
proteins were washed with binding buffer containing 5 mM imidazol; Wash: the unbound 
proteins were washed with wash buffer containing 50 mM imidazol; Elution: the bound proteins 
were eluted with elution buffer containing 400 mM imidazol. (b). SDS-PAGE gel analysis of 
affinity chromatography purification of recombinant antiA-scFv. Gel lanes were normalized to 
equivalent volume. TS. Total input protein (before loading to the column); F1-F2. Flow-
through; W. Washing fractions; E1-E7. Elution fractions; M. Molecular Weight Marker 
 
Purification of recombinant antiA-scFv 
fused with SUMO 
The SUMO vector, as designed, has N-
terminal polyhistidine (6xHis) tag (Dang et 
al., 2018) which facilitates purification of 
recombinant fusion protein with Ni-
Sepharose resin. Therefore, total soluble 
fusion protein SM/antiA-scFv containing 
the 6xHis tag was purified through Ni-
Sepharose affinity chromatography. The 
protein SM/antiA-scFv bound efficiently to 
the Ni
2+ 
resin and was not washed off during 
loading and washing steps. However, very 
little amount of protein was obtained in 
elution step in comparison with the high 
amount of total protein loaded to the 
column. Purification of this fusion protein 
using ion-exchange column was also 
unsuccessful. The firm interation between 
sepharose-based resin and SM/antiA-scFv 
was only disruped when using denaturants 
(data not shown). 
Thus, the purification of SM/antiA-scFv 
was conducted using precipitation with 
ammonium sulfate. The largest amount of 
SM/antiA-scFv was precipitated by 20% 
(NH4)2SO4. In contrast, most of the proteins 
from E. coli and chaperone were precipitated 
at a higher concentration of ammonium 
sulfate (Fig. 2a). This result suggested the step 
for precipitation and removal of some 
undesired proteins from solution at 15% 
(NH4)2SO4, followed by the increase of 
(NH4)2SO4 to 20% to precipitate most of 
SM/antiA-scFv.  
By centrifugation, precipitated 
SM/antiA-scFv was collected, washed and 
cleaved by SUMO protease. After cleaving 
the SUMO tag, anti-scFv was released from 
the fusion with SUMO, corresponding to a 
~33 kDa band in SDS-PAGE gel. Protein 
antiA-scFv, in insoluble form, was easily 
separated from other constituents of the 
cleavage mixture by centrifugation and 
washed in buffer containing Tween 20 and 
Triton X100. In this wash step, some protein 
impurities were dissolved and separated from 
the antiA-scFv precipitate. The target protein 
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was solubilised in buffer containing 5% 
glycerol, 71.5 mM mercaptoethanol and 
0.05% SDS and finally dialysed against PBS 
pH 7.4 with 5% glycerol (Fig. 2b). The 
obtained protein antiA-scFv after purification 
was tested for its bioactivity.  
The final yields of purified antiA-scFv 
was approximately 64.9 mg/L of bacterial 
culture. This is relatively high compared to 
the productivity obtained by other studies at 
the same flask scale fermentation (Frenzel et 
al., 2013). For example, scFv was produced 
with a yield of 50 mg/L (Golchin et al., 2012) 
or 10.2 mg/L (Bu et al., 2013). In another 
research, only 0.5−1 mg scFv was recovered 
from 1 L of culture (Wu et al., 2007). 
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Figure 2. (a) Purification of SM/antiA-scFv by ammonium sulfate precipitation. TS. Total 
soluble protein SM/antiA-scFv; Lanes 1−10. Precipitation fractions at different (NH4)2SO4 
concentration: 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%; (b). SDS-PAGE 
analysis of SM/antiA-scFv cleaved by SUMO protease and purified antiA-scFv. Lane 1. 
SM/antiA-scFv, Lane 2. SM/antiA-scFv cleaved by SUMO protease, Lane 3. Soluble fraction 
after cleaving, Lane 4. Insoluble fraction seperated from cleavage mixture was washed in buffer 
containing Tween 20 and Triton X100, Lane 5. Insoluble fraction seperated from cleavage 
mixture (containing antiA-scFv) was solubilised in buffer containing 5% glycerol, 71.5 mM 
mercaptoethanol and 0.05% SDS, Lane 6. The remain insoluble fraction after the solubilization 
of antiA-scFv;  (c). Western blot analysis of purified antiA-scFv. Lane 1. Total soluble protein 
SM/antiA-scFv, Lane 2. 20% ammonium sulfate precipitation fraction (containing SM/antiA-
scFv), Lane 3. Purified antiA-scFv, M. Molecular Weight Marker (Fermentas) 
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Figure 3. Nondenaturing PAGE analysis to 
demonstrate the polymezation of antiA-scFv. 
Lanes 1 and 2. 7 and 15 µg of purified antiA-
scFv, respectively; M. protein marker 
(Fermentas) 
 
Besides, nondenaturing PAGE analysis 
was used to visualize anti-scFv 
polymerization and the polymers were 
appeared as slow migrating bands on the gel 
forming a “ladder” of polymers with higher 
than 100 kDa in size (Fig. 3). From this result, 
we predicted that purified antiA-scFv was 
produced in a polymer-protein conjugate 
which could be applied directly to biological 
activity test. 
Binding assay of recombinant antiA-scFv   
To analyse the biological activity of 
purified antiA-scFv, the specific binding 
activity of this recombinant protein was 
assessed by ELISA using pure antigens 
A/BSA, B/BSA and BSA. The higher signal 
of antiA-scFv bound to A/BSA and B/BSA 
antigen, at 0,403 and 0,338 respectively, 
was obtained comparing to BSA and 
negative control (wells without antigen). 
From this result, antiA-scFv bound to both 
A/BSA and B/BSA but showed 1.2-fold 
higher binding ability to A/BSA compared 
to B/BSA (Table 2). 
 
Table 2. The binding activity of recombinant antiA-scFv was evaluated by ELISA. 
Samples A/BSA B/BSA BSA 
Positive 
sample 
Positive control- 
from company 
TN1 0,396 0,353 0,036 0,663 0,838 
TN2 0,389 0,353    
TN3 0,409 0,327 0,059 0,709 0,840 
TN4 0,418 0,319    
TB 
0,403 ± 
0,013 
0,338 ± 
0,018 
0,048 ± 0,016 0,686 ± 0,033 0,839 ± 0,001 
Note: TN1- TN4. 4 replicates of each sample, 2 replicates for control. TB. average value calculated from 
all replicates for each sample, p-value < 0,01. 
 
             a. ELISA test result                                           b. Sample sites on ELISA dics                 a. Kết quả thí nghiệm ELISA                                    b. Ghi chú mẫu trên đĩa ELISA 
 
1 2 3 4 5 6
A A/BSA B/BSA BSA ĐC(-)
PBS
ĐC(+)
Mẫu
ĐC(+)
Hãng
B A/BSA B/BSA
C A/BSA B/BSA BSA ĐC(-)
PBS
ĐC(+)
Mẫu
ĐC(+)
Hãng
D A/BSA B/BSA
Figure 4. The binding activity of recombinant antiA-scFv was evaluated by ELISA using pure  
Figure 4. The binding activity of recombinant antiA-scFv was evaluated by ELISA using pure 
antigens from red blood cells 
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In addition, the functional activity of the 
recombinant antiA-scFv was also assessed by 
a hemagglutination assay using type A, B and 
O human red blood cells. The results show 
that recombinant antiA-scFv showed 
hemagglutination of red blood cells at 
concentrations of or higher than 3.12 µg with 
type A, 6.25 µg with type B, and 25 µg with 
type O (Fig. 5a).  
From the binding assays using pure 
antigen and red blood cells, recombinant 
antiA-scFv has low specificity in binding 
activity. 
In other experiment, the incubation of 
antiA-scFv with EGS (an agent allowing 
protein to be trimeric by chemical cross-
linking) increased its agglutination ability 
when hemagglutination of type A red blood 
cells starting from a concentration of 1.56 µg 
of antiA-scFv. When red blood cells was pre-
treated with ficin, this activity was even 
increased further when hemagglutination 
started to happen from a concentration of 0.78 
µg of antiA-scFv. While EGS is a bifunctional 
linker which facilitates tertiary structure of 
protein, ficin is known to enhance reactivity 
caused by antibodies against ABO blood 
group system. Therefore, the addition of EGS 
and the use of ficin pre-treated red cells will 
enhance the binding activity of recombinant 
antiA-scFv to the specific antigen on the 
surface of red blood cells in hemagglutination 
assay (Fig. 5b). 
The key difference between A and B blood 
antigens is a singe sugar at the end of the 
antigen. To be specific, type A antigen has a 
terminal N-acetylgalatosamine whereas type B 
antigen has a terminal galactose. Since 
galactosamine is very similar to galactose, 
there is evidence that recombinant anti-A 
antibodies can elicit a cross-reaction with the 
B-specific terminal residue. Besides, the 
incomplete/incorrect formation of the 2 
disulfide bridges structure could be responsible 
for the lack of specificity of recombinant anti 
A-scFv. Several approach could be considered 
to make  E. coli more suitable for expression of 
disulfide-rich protein. These include 
introducing disulfide isomerase protein  to 
enhance disulfide bond formation. 
 
                             a                                                                               b 
 
6,25 µg 3,12 µg 1,56 µg 0,78 µg 0,39 µg 0,2 µg
6,25 µg 3,12 µg 1,56 µg 0,78 µg 0,39 µg 0,2 µg
antiA-scFv_EGS + HCA
antiA-scFv_EGS + HCA-fixin
 
Figure 5. Hemagglutination assay of recombinant antiA-scFv. (a) Binding activity of 
recombinant antiA-scFv with antigens type A, B and O of red cells. (b) Binding activivy of 
recombinant antiA-scFv incubated with EGS with antigens type A, B and O of ficin pre-treated 
red cells 
 
To the best of our knowledge, currently, 
no publication has reported the production of 
recombinant scFv of human antibody against 
antigens in the ABO-blood group but Rh-type 
blood system (Furuta et al., 1998).  
CONCLUSION 
Recombinant single chain antibody that 
recognized A-antigen (antiA-scFv) in ABO-
blood system was expressed and purified with 
the purity of 89% and the yield of 64.9 mg/l 
Duong Thu Huong et al. 
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of culture. This recombinant antiA-scFv 
showed ability to hemagglutinate antigens of 
red blood cells but the binding specificity of 
its to A-antigen was limited.   
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